For almost 100 years, great strides were made in developing new vaccines and antibiotics to significantly reduce the global threat that deadly viruses and bacteria once posed to humanity. These "wonder drugs" offered the hope of beating or managing conditions once considered a death sentence, such as tuberculosis, influenza, and HIV. However, antibiotics are rapidly losing their effectiveness and few manufacturers are jumping in to develop new ones. Moreover, new vaccines face significant market and societal acceptance challenges, not to mention the lack of market incentives for vaccines to treat emerging pathogens. In order to stay ahead of the next global health threat, what innovative business models and financial incentives do we need to get new medications through the R&D pipeline and to those in need? Furthermore, how can we pool multi-sector resources and intellectual capital without reinventing the wheel?